It is a dream of neurologists to cure degenerative diseases. The big brothers, Alzheimer’s and Parkinson’s disease have always been a huge burden of the population but are now, in the millennium of increasing population age becoming a scourge of humanity. While everybody is acknowledging this, both PD (1) and AD (2) communities of clinician researchers and basic researchers are preparing to attack the problem fundamentally frequently unnoticed by the general neurology community.

As you may have seen the NEW Guideline:  EAN guidelines on central neurostimulation therapy in chronic pain conditions has just been published in the October issue

It is a dream of neurologists to cure degenerative diseases. The big brothers, Alzheimers’ and Parkinsons’ disease have always been a huge burden of the population but are now, in the millennium of increasing population age becoming a scourge of humanity. While everybody is acknowledging this, both PD1 and AD2 communities of clinician researchers and basic researchers are preparing to attack the problem fundamentally frequently unnoticed by the general neurology community.

For October 2016 we have selected: Sevigny J, Chiao P, Bussiere T, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature 2016;537:50-56. Alzheimer’s disease (AD) is the most frequent neurodegenerative disorder. It is also extremely disabling with severe impact of the quality of life of patients and caregivers. The main pathological process is related to the toxic deposition of amyloid-β plaques and neurofibrillary tangles. No effective treatment is currently available to slow down the disease progression.

EANpages has the honor and the pleasure to introduce this virtual Round Table, composed by some members of the EAN Scientific Panel on Dementia and Cognitive Disorders, who are discussing the Paper of the Month, in addition to the comments of the Presidential Page. We thank the Panel for their enthusiastic participation and we invite all EAN members to participate with sending their comments.

David B. Vodušek (DV): EFNS has been a founding member of EBC, and its successor EAN continues to be an actively involved member society. Nevertheless, many of our readers would appreciate to hear your views on what is EBC, its mission and how it gets this accomplished? David Nutt (DN): The ultimate reason behind all EBC actions is to improve the condition of those living with brain disorders and to reduce prevalence of brain diseases all together.

By Jose E. Martínez-Rodríguez
More than 9000 participants attended the 32nd Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS) and the 21st Annual Conference of Rehabilitation in MS in London from September 14th to17th.… Continue Reading

Cruccu G, Garcia-Larrea L, Hansson P, Keindl M, Lefaucheur JP, Paulus W, Taylor R, Tronnier V, Truini A, Attal N. EAN guidelines on central neurostimulation therapy in chronic pain conditions. Eur J Neurol. 2016 Aug 11. Why these guidelines ?… Continue Reading